Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.

Publication Type:

Journal Article

Source:

American journal of hematology, Volume 89, Issue 10, p.964-8 (2014)

Keywords:

2014, Center-Authored Paper, Clinical Research Division, Flow Cytometry Core Facility, July 2014, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Specimen Processing Core Facility

Abstract:

Despite being considered 'good-risk' acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85% respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.